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a b s t r a c t 
Background: Mental disorders affect millions of people worldwide. Their etiology is complex and the fact that 
the main effects occur in the brain hampers biochemical diagnosis. Therefore, biomarker finding in peripheral 
fluids such as serum or saliva is desirable. Here, we searched for biomarkers in salivary extracellular vesicles 
(EVs). Then, we focused on the protein M6a, related to neuronal connectivity and associated with several mood 
disorders to study its usefulness in saliva for the diagnosis of depression and anxiety. 
Methods: Biomarker candidates were searched by proteomic analysis of human salivary EVs. M6a presence in 
salivary EVs was validated by transmission electron microscopy and Western blot. M6a levels were measured by 
ELISA in saliva samples of 88 individuals classified as control, depressed or anxious. 
Results: We identified ten protein candidates in salivary EVs: OLIG2, PMP2, CNP, CAMK2A, SLC25A22, MLLT11, 
HTR2A, MAPT, ATP2B2 and M6a, all associated with emotional disorders. Salivary M6a levels positively corre- 
lated with the scores for the perceived stress scale in individuals diagnosed with depression. Furthermore, saliva 
samples of depressed patients treated with serotonin reuptake inhibitors (SSRI) or benzodiazepines differed in 
their M6a levels with respect to untreated patients. 
Limitations: The main limitation of this study lies in the low number of patients involved, which warrants repli- 
cation. 
Conclusions: Salivary EVs contain promising biomarker candidates for mental disorders. Further studies will help 
validate them for their potential use in diagnosis. Our results lead us to propose M6a as a workable molecule to 



























Mental disorders affect hundreds of people around the world and 
ave a profound impact on productivity, motivation and outcome of 
everal chronic diseases. Although there are many subtypes and more 
han one etiology, it is generally accepted that chronic stress is a key 
actor in their onset ( McEwen, 2008 ; Schneiderman et al., 2005 ). Mood 
isorders can affect adults, adolescents and children and have a high 
ate of relapse and recurrence. Several studies show that prompt treat- 
ent and follow-up result in better outcomes, making early detection 
f afflicted patients critical ( Duval et al., 2006 ). At present, the diag- ∗ Corresponding author. 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) osis and treatment of mental disorders is still based on the subjective 
linical evaluation of symptoms and not on a biochemical assessment. 
here are virtually no commercial kits available for mood-disorder diag- 
osis. Although many studies have analyzed different biological mark- 
rs (biomarkers), none was conclusive regarding how biologic informa- 
ion can be used to enhance diagnosis, treatment and prognosis ( Dhama 
t al., 2019 ; Rodriguez Cerdeira et al., 2017 ; Strawbridge et al., 2017 ).
 stress biomarker would indicate that an individual is not in physio- 
ogical comfort and that different mechanisms are activated to restore 
omeostasis ( Dhama et al., 2019 ; McEwen et al., 2015 ). Beyond HPA 
xis activation markers, such as cortisol, immune system molecules and 
utonomic nervous system hormones and neurotransmitters have been 
sed as biomarkers ( Dhama et al., 2019 ; Nater et al., 2013 ). The main
isadvantage of such molecules is the need for invasive blood sampling. tember 2020 
article under the CC BY-NC-ND license 







































































































herefore biomarkers from easy accessible fluids are gaining popular- 
ty. Saliva sampling methods, as compared to blood sampling, are less 
nvasive, simpler, safer, less stressful and do not require any particular 
raining or equipment ( Han et al., 2018 ; Ivkovic et al., 2015 ; Katsani
nd Sakellari, 2019 ). Most compounds that appear in blood can also 
e identified in saliva, although at different concentrations ( Loo et al., 
010 ). In addition, almost 40% of the proteins that have been suggested 
o be candidate markers for diseases can be found in saliva ( Katsani and 
akellari, 2019 ). However, biomarker detection in saliva is hindered by 
he presence of proteins such as alpha-amylase that may mask other 
roteins with low expression ( Deutsch et al., 2008 ; Han et al., 2018 ).
xtracellular vesicles (EVs) could overcome this disadvantage acting 
s reservoirs of molecules and allowing their detection, which would 
therwise be overlooked due to their dilution in the whole fluid. EVs 
re lipid bilayer-delimited particles that carry proteins, nucleic acids 
nd lipids from their original cell in both physiological and patholog- 
cal conditions. Thus, EVs participate in intercellular communication 
 Boukouris and Mathivanan, 2015 ). 
Brain EVs can reach the oral cavity and can be detected in saliva 
 Cheng et al., 2019 ). EVs have been used in the diagnosis of diseases such
s Alzheimer’s and Parkinson’s, prion disease, traumatic brain injury 
nd glioma ( Cheng et al., 2019 ; Han et al., 2018 ; Saman et al., 2012 ;
tern et al., 2016 ), making salivary EVs an attractive source to look for 
iomarkers related to brain disorders. 
Psychiatric disorders appear to be the result of the disruption of 
omeostatic mechanisms that maintain synaptic plasticity ( Duman and 
ghajanian, 2012 ) which implies changes in genes related to such path- 
ays, including the gene for the neuronal glycoprotein M6a. M6a par- 
icipates in neuronal differentiation, filopodium/spine formation and 
ynaptogenesis and is also a stress-regulated protein ( Alfonso et al., 
006 , 2005 , 2004 ; Brocco et al., 2010 ; Formoso et al., 2015 ). More-
ver, the changes observed in M6a levels in the hippocampus of stressed 
nimals were similar to those observed in the serum of such animals 
 Monteleone et al., 2017 ). In humans, M6a mRNA is downregulated 
n the hippocampus of depressed suicides ( Fuchsova et al., 2015 ) and 
 duplication of M6a gene was associated with mental retardation 
 Gregor et al., 2014 ). Polymorphisms in M6a gene have been associated 
ith schizophrenia ( Boks et al., 2008 ), claustrophobia ( El-Kordi et al., 
013 ) and bipolar disorder ( Greenwood et al., 2012 ; Khalid and Sezer- 
an, 2020 ). Remarkably, M6a has been identified by us and others in 
Vs ( Gonzales et al., 2010 ; Lazar et al., 2015 ; Monteleone et al., 2017 ).
In this work, we aimed to find new biomarkers for mood disorders by 
roteomic analysis of extracellular vesicles isolated from human saliva. 
hen, in a pilot study, we evaluated the usefulness of one of the can- 
idates, the glycoprotein M6a, as biomarker for depression and anxiety 
nd treatment efficacy. 
. Methods and materials 
.1. Extracellular vesicle isolation 
Whole saliva (15 ml) was collected by drooling in a sterile Falcon. 
Vs were isolated as previously described ( Théry et al., 2006 ) with 
light modifications. Collected saliva was diluted by half in PBS and 
entrifuged at 2,600 × g for 30 min at 4 °C to pellet cells, debris and bac-
eria. Supernatant was transferred to clean tubes and ultracentrifuged at 
20,000 × g for 120 min at 4 °C. Pellets containing extracellular vesicles 
ere resuspended in sterile PBS. Characterization of EVs was done by 
ransmission electron microscopy (TEM) and Western blot (see below). 
.2. Proteomics 
LC-MS/MS analysis of total salivary EVs were done at ITSI service 
ITSIBiosciences, Johstown, PA). The received protein list was ordered 
ccording to the NSAF, which allows the comparison of abundance of 
ndividual proteins in multiple independent samples. 2 .3. Bioinformatics tools 
Uniprot, Human Protein Atlas and Genecard databases were used 
o complete protein name or tissue and expression sites. The en- 
ichment in EV proteins was checked by comparison with Exo- 
arta Top100 list ( http://www.exocarta.org , ( Mathivanan and Simp- 
on, 2009 )). Enrichment of Gene Ontology (GO) terms (Gene Ontol- 
gy Consortium, 2015) was carried out with Panther Classification 
ystem http://www.pantherdb.org/ ( Thomas et al., 2003 ).The brain- 
pecific proteome consisting of the 419 brain-enriched genes was down- 
oaded from the Human Protein Atlas Database ( Uhlen et al., 2017 ) 
Human Protein Atlas available from www.proteinatlas.org ). Venn di- 
grams were created with Venny ( Oliveros, n.d. ). The disease related 
athways were analyzed with the ToppGene Suite portal ( Chen et al., 
009 ). 
.4. Transmission electron microscopy (TEM) 
TEM was performed at the LANAIS-MiE-IBCN (SNM-CONICET) fa- 
ility (Buenos Aires, Argentina). Sample preparation was done accord- 
ng to Théry 2006 ( Théry et al., 2006 ). EVs were fixed with 4% EM-
rade PFA in TEM-buffer (50 mM HEPES, pH 6.5) and absorbed in 
O coated copper grids (200 mesh). Samples were post-fixed in 1% 
M-grade glutaraldehyde in TEM-buffer and rinsed with deionized wa- 
er, then stained with 2% Uranyl acetate. Micrographs were acquired 
n a Carl Zeiss EM 109T transmission electron microscope operating 
t 80 kV and equipped with a Gatan ES1000W (11 Mpixel) digital 
amera. 
For immunogold stain, M6a antibody (MBL International, Woburn, 
A) was used and complexes were detected using 18 nm gold conju- 
ated anti-rat IgG antibody (Jackson ImmunoResearch, WestGrove, PA, 
SA). 
.5. Western blot and antibodies 
Primary antibodies used were: anti-M6a: polyclonal rabbit anti- 
ody against C-terminus of M6a developed in our laboratory (1/500); 
nti-flotillin-1 monoclonal mouse antibody (1/1000, BD Bioscience, 
610820) and anti-CD9, clone B2C11 (1/250, DSHB Hybridoma Prod- 
ct B2C11, deposited by P.H. Patterson). Detection was done with an 
dyssey infrared imaging system (LI-COR Biotechnology, Nebraska, 
S). Anti-rabbit IgG or anti-mouse IgG IRdye 680 LI-COR P/N 925- 
8021 and P/N 925-68020 were used. 
Blot images were digitally processed with Image J software 
 http://rsb.info.nih.gov/ij/ ) to show each band more clearly. In all 
ases, processing was applied equally across the entire image. Origi- 
al blot images without digital processing are shown in Supplementary 
ig 1. 
.6. Participants and collection of saliva 
The work described below has been carried out in accordance with 
he Code of Ethics of the World Medical Association (Declaration of 
elsinki). 
.6.1. Ethics approval and consent to participate 
Procedures involving human participants were evaluated and ap- 
roved by the Research Committee and the Bioethics Committee of 
he San Juan de Dios Hospital House (Protocol CEI 004/2017, ap- 
roved on April 14th 2017). Participants were informed about the 
urpose of the investigation and were asked to sign a consent form. 
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Table 1 
Overview summary of participants. Median (Q1-Q3) is reported in each case. 
Female Male 
N 62 26 
Age median (IQR) 59 (39–67) 62 (37–68) 
Individuals under pharmacological treatment (n) 31 8 
Years of treatment median (IQR) 2.3 (0.2–5.3) 2.6 (0.6–4.8 ) 
Depressed (n) 24 7 
Anxious (n) 26 13 






























































































ther than saliva collection, there were no study-related consequence 
nterventions. 
.6.1.1. Healthy subjects. Twenty-five volunteers self-identified as 
ealthy (14 women, 11 men) between 25–75 years old collected saliva 
sing a commercially available device (Salivette R ○; Sarstedt, Rommels- 
orf, Germany). They were requested not to eat or collect the sample 
mmediately after brushing teeth or after any activity that may cause 
ums to bleed. Salivette R ○ devices were centrifuged at 1,000 × g for 2 
in upon reception according to manufacturer’s instructions. To prevent 
egradation of critical biological molecules (e.g., RNA and proteins) due 
o freeze and thaw cycles, the clear effluent was divided in 50 𝜇l working
liquots and stored until use at − 20°C in a freezer designated for human 
amples storage only. Saliva samples were used for M6a determination 
ccording to ELISA kit #MBS9312190 manufacturer instructions. (My- 
ioSource, San Diego, CA, US). Cortisol levels in these samples were 
etermined by ECL (División de Endocrinología – CEDIE, Hospital de 
iños "Dr. Ricardo Gutiérrez", CABA, Argentina). 
.6.1.2. Patients and control individuals. Eighty-eight individuals were 
ecruited (62 women, 26 men). Further details of the cohort are shown 
n Table 1 . After a directed anamnesis and clinical examination and 
ased on the Diagnostic and Statistical Manual of Mental Disorders 
 
th Edition (DSM-V) ( American Psychiatric Association, 2013 ) subjects 
ere classified in 5 groups: depressed (if they had Major Depressive 
isorder, MDD), anxious (if they have Generalized Anxiety Disorder, 
AD), depressed or anxious under medical treatment or controls. Two 
hysicians from the San Juan de Dios Hospital did the assessments. De- 
ressed individuals were mild or moderate in severity. Depressive and 
nxious patients under medical treatment were later classified accord- 
ng to the drug they received: Selective Serotonin Reuptake Inhibitors 
SSRI: Fluoxetine, Escitalopram, Paroxetine) or Benzodiazepines (Alpra- 
olam, Clonazepam). Individuals with cognitive disorders, treated with 
lucocorticoids, with recent surgery proceedings and pregnant or lac- 
ating women were excluded. 
The following psychometric test were administered to all individuals: 
SS, Perceived Stress Scale which is a validated measure to assess the 
evel of subjective life stresses ( Cohen et al., 1983 ); the Beck Depression 
nventory (BDI) which is a widely used questionnaire assessing anxiety 
everity and hospital anxiety and depression scales (HADS-A and HADS- 
), which focus on the evaluation of the cognitive aspects of anxiety and 
epression ( Bjelland et al., 2002 ). 
.7. Statistical analysis 
Statistical analysis and graphs were carried out with GraphPad Prism 
ersion 6.01. All data were subjected to normality and equal variance 
esting using IS version 2010 (Infostat software, Grupo InfoStat, FCA, 
niversidad Nacional de Córdoba, Argentina). Statistical significance 
as determined by Mann-Whitney U test. Non-parametric one-way anal- 
sis of variance (Kruskal-Wallis) test followed by Dunn’s multiple com- 
arison tests was used to compare more than 2 groups. Correlations 3 ere assessed using Spearman’s correlation coefficient ( r s ). For all tests, 
 p < 0.05 was considered statistically significant. 
. Results 
.1. Salivary EVs contain several brain proteins related to psychiatric 
isorders 
For candidate biomarker discovery in saliva, we used an EV-based 
trategy. Extracellular vesicles (EVs) from a pool of saliva samples from 
our healthy donors (women and men) were isolated and subjected to 
roteomic analysis. Among the identified proteins (4380), we found, 44 
f the considered TOP100 EV markers (proteins often identified in EVs) 
rom the Exocarta database (Supplementary Fig 2). This result further 
onfirms that the sample analyzed contained EVs. 
Then, to identify the most frequently detected proteins, we set a cut- 
ff in a Normalized Spectral Abundance Factor (NSAF) of 10 − 6 and ob- 
ained a list of 498 proteins. The cellular components, biological pro- 
esses and molecular functions of these proteins were analyzed with 
he PANTHER classification system ( Thomas et al., 2003 ). Most of them 
ell in the category “cell ” (34.5%, Fig. 1 A). The rest was classified as 
xtracellular (10.3%), membrane (37.9%), organelle (6.9%), synapse 
3.4%) or involved in protein complexes (3.4%, Fig. 1 A). EV proteins 
ere involved in 11 types of biological processes ( Fig. 1 B), mainly bio- 
ogical regulation and signaling (27.3 and 12.7% respectively). In terms 
f molecular functions, the proteins were mainly associated to binding 
nd catalytic activity categories (32.6 and 26.1% respectively; Fig. 1 C). 
esides their diversified biological processes and molecular functions, 
hese proteins have been involved in more than ten different pathways. 
everal proteins were in the glutamate receptor pathway, inflammation 
ediated by chemokine and cytokine signaling pathway and serotonin 
eceptor pathway ( Fig. 1 D). 
To investigate if there were brain proteins among salivary EV pro- 
eins, our 498-protein list from the EV proteome was compared with 
he list of brain-enriched proteins (mRNA levels 5-fold or higher in the 
rain than other tissues) from the Human Protein Atlas database. Ten 
roteins were identified: 5-Hydroxytryptamine Receptor 2A (HTR2A), 
alcium/Calmodulin Dependent Protein Kinase II Alpha (CAMK2A), 
lasma Membrane Calcium-Transporting ATPase 2 (ATP2B2), Oligo- 
endrocyte Transcription Factor (OLIG2), Peripheral Myelin Protein 
 (PMP2), 2 ′ ,3 ′ -Cyclic Nucleotide 3 ′ Phosphodiesterase (CNP), Gluta- 
ate Solute Carrier family 25 member 22 (SLC25A22), Microtubule- 
ssociated Protein Tau (MAPT), Myeloid/Lymphoid Leukemia Translo- 
ated To 11 (MLLT11) and Glycoprotein M6A (GPM6A) ( Fig. 1 E-F, Sup- 
lementary Fig 3). ToppGene analysis indicated an association of candi- 
ates with psychotic disorders ( Fig. 1 G). The aforementioned biological 
nd molecular functions coupled to the ToppGene prioritization suggest 
hat salivary EVs carry brain proteins related to neuropsychiatric dis- 
ases. 
As mentioned, the neuronal glycoprotein M6a was found among 
hem. Since our group has extensively studied the role of M6a in neu- 
onal architecture and in several animal models to induce depression- 
ike symptoms, we centered our study on this glycoprotein in the next 
xperiments. 
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Fig. 1. Saliva contains brain-enriched proteins with potential use as mood-disorder biomarkers. PANTHER generated pie charts (A) Cellular component. (B) Biological 
process. (C) Molecular process. (D) Pathways. (E) Venn diagram showing overlap between the Human Protein Atlas 419 brain-enriched proteins and the salivary 
EV proteins with NSAF > 10 − 6 . (F) List of the ten identified candidates. (G) ToppGene Suite analysis of the ten candidates shows that they are related to several 
cognitive disorders. 
4 
M.C. Monteleone, S.C. Billi, L. Viale et al. Journal of Affective Disorders Reports 1 (2020) 100003 
Fig. 2. M6a can be detected in salivary 
EVs. ( A) TEM representative images of 
EVs isolated from saliva. In the magnifica- 
tion, round shaped vesicles with the clas- 
sical cup shaped morphology (indicated 
with arrows) can be observed. This in- 
dicates that intact vesicles were isolated 
rather than cell debris or bacteria. Scale 
bar 100 nm. (B) Western blot of extra- 
cellular vesicles showing classical mark- 
ers Flotillin-1 and CD9. Membrane was 
cut at ~40 kDa. Upper membrane was 
reacted with anti-Flotillin-1 antibody and 
lower membrane with anti-CD9 antibody. 
M: molecular weight marker. (C) Immuno- 
gold labeling of M6a in the isolated EVs. 
Arrows show the immunoreactive com- 
plexes. These are not seen when primary 
antibody is omitted. Scale bar 100 nm. 
(D) Western blot of M6a in EVs. EVs, as 
well as the supernatant from the final step 
(SN) were loaded on a 12% SDS gel. Same 
amount of protein was loaded in each lane. 
As expected, no signal was detected in the 
supernatant (SN) of the isolation protocol. 
M6a signal was easily detected in EVs. Mul- 





























Scores obtained for each test in control, depressed and anxious patients. Me- 
dian (Q1-Q3) is indicated for each case. Non-parametric ANOVA followed 
by Dunn’s multiple comparison tests were used. Asterisks indicate statis- 
tical differences compared to control values. HADS D p = 0.002; HADS A 
p = 0.0094; PSS p = 0.0022 (Dunn’s multiple comparison test C vs A; C 
vs D); BECK p < 0.0001 (Dunn’s multiple comparison test C vs A; C vs D). 
Control Depressed Anxious 
HADS-D 2.0 (1.0–4.5) 7.0 (5.0–12.0) ∗ ∗ 4.5 (2.3–9.0) 
HADS-A 6.5 (4.0–8.3) 7 (5.0–9.0) 10.5 (6.3–12.8) ∗ 
PSS 10.5 (7.8–16.3) 23.0 (19.0–29.0) ∗ ∗ 19.5 (13.5–25.0) ∗ 















.2. M6a can be detected in salivary EVs (Validation of proteomics) 
Extracellular vesicles from saliva were obtained by differential 
entrifugation. Transmission electron microscopy (TEM) was used to 
valuate EVs morphology. Under TEM, a round morphology was ob- 
erved, several displaying a cup-shaped appearance characteristic of EVs 
 Fig. 2 A). To further characterize EVs, we analyzed the presence of rep- 
esentative membrane markers, such as CD9 (~25 kDa) and Flotilin- 
 (~48 kDa). These markers were identified by proteomics and there- 
ore were validated by Western blot. Fig. 2 B shows the presence of both 
arkers in EVs. 
Next, we assessed the presence of M6a in salivary EVs by immuno- 
old labeling. Isolated EVs showed M6a immunoreactive complexes (ar- 
ows) not detected when the primary antibody was omitted (control, 
ig. 2 C). Western blot analysis showed that while no signal was de- 
ected in the supernatant of 120,000 × g ultracentrifugation (SN), reac- 
ivity against 35–40 kDa bands (the expected sizes for M6a) was easily 
bserved in EVs (stars in Fig. 2 D). Multiple M6a bands are normally ob- 
erved due to posttranslational modifications. Altogether these results 
onfirm M6a presence in salivary EVs. 
.3. M6a can be detected in whole human saliva 
Since a simple method of diagnosis ideally requires minimum sam- 
le processing, we next evaluated if M6a could be detected in whole 
aliva. M6a levels were determined in saliva samples donated by 25 
ealthy volunteers (11 men, 14 women between 25–75 years old). 
onors were not under any antidepressant treatment and showed corti- 
ol levels within the normal range according to the test applied (morn- 
ng range 3.3–34.8 nmol/l; night range 1.7–7.7 nmol/l) (Supplemen- 
ary Fig 4). M6a levels were measured using a commercially available 
nzyme-linked immunosorbent assay (ELISA) ( Fig. 3 A). M6a levels were 
5.4 ng/ml (10.6–53.0) for men and 15.3 ng/ml (3.9–57.8) for women. 5 6a mean levels did not differ between men and women. Therefore, in 
urther analysis men and women were studied together. Healthy candi- 
ate M6a levels ranged between 0–110 ng/ml. 
.4. M6a levels positively correlates with stress perception in depressed 
atients 
Next, we analyzed M6a in saliva samples of patients. Participants 
ere diagnosed by clinicians as depressed, anxious or no depressed nor 
nxious (control group). Participants completed the Hospital Anxiety 
nd Depression Scales (HADS-A and HADS-D, respectively), the Beck De- 
ression Inventory (BDI-II) and the Perceived Stress Scale (PSS). Overall, 
cale scores ( Table 2 ) agreed with clinician diagnoses based on clinical 
xamination. 
We found no differences in M6a levels in depressed patients or anx- 
ous patients compared with control subjects (non-parametric ANOVA 
 = 0.3516) ( Fig. 3 B) 
To find out if any of the scale scores correlated with salivary M6a 
evels, we carried out Spearman correlation analysis. For depressed pa- 
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Fig. 3. M6a can be detected in human saliva and correlates with PSS score in patients diagnosed with depression, with HADS-D in patients with score > 7 and is modulated by 
classic antidepressants such as SSRI and benzodiazepines. ( A) ELISA determination M6a levels in saliva in women and men. No differences were detected; therefore men 
and women were studied together. (B) M6a levels do not differ between control subjects ( n = 18) and patients diagnosed with anxiety ( n = 20) or depression ( n = 11) 
(Non-parametric ANOVA p = 0.3516). (C) M6a positively correlates with PSS score in patients diagnosed with depression (Spearman test, r 2 = 0.79 p = 0.037). D) M6a 
levels do not correlate with HADS-D score in the depressed group (Spearman test r 2 = 0.338, p = 0.308). However in borderline or caseness patients (HADS- D > 7) a 
strong positive correlation was detected (Spearman test r 2 = 0.844, p = 0.0168) (E). (F) No differences were detected for M6a levels in anxious patients under SSRI 
or B treatment (Non-parametric ANOVA p = 0.9552). (G) M6a levels were significantly altered by SSRI and B although with an opposite pattern (Non-parametric 
ANOVA p = 0.0002. Dunn´s multiple comparison test ∗ C vs D + B; ∗ D vs D + SSRI; ∗ ∗ ∗ D + SSRI vs D + B). These results show that salivary M6a levels might be modulated 




















ients, we found a positive correlation between M6a levels and the 
SS score ( Fig. 3 C Spearman test, r 2 = 0.7927, p = 0.037). Given the
ink between chronic stress and depression ( Bartolomucci and Leop- 
rdi, 2009 ; Tafet and Bernardini, 2003 ; Yang et al., 2015 ), we next
nalyzed the correlation between the M6a levels found in depressed pa- 
ients and the HADS-D score. According to HADS-D score, people are 
lassified as normal (0–7), borderline (8–10) or caseness (12–21). Al- 
hough we did not find correlation between HADS-D score in depressed 
atients and M6a levels ( Fig. 3 D, Spearman correlation test r 2 : 0.3387,
 = 0.3083), we did find a correlation when patients were classified by 
he score. HADS-D scores higher than 7 (i.e. borderline and caseness 6 atients) correlated with M6a levels ( Fig. 3 E, Spearman test r 2 : 0.8444, 
 = 0.0168). 
.5. M6a might be useful to evaluate antidepressant efficacy 
We next analyzed the effect of pharmacological treatment on M6a 
evels. Patients (anxious or depressed) treated with selective serotonin 
euptake inhibitors (SSRI) or benzodiazepines (B) were included in the 
nalysis. No differences in M6a levels were observed for patients di- 
gnosed with anxiety under treatment with SSRI or benzodiazepines 
 Fig. 3 F, non-parametric ANOVA p = 0.9552). 
























































































































On the other hand, among depressed patients, we found that M6a lev- 
ls were significantly lower in those under SSRI treatment in comparison 
o those without treatment. No differences in M6a levels were observed 
etween SSRI-treated patients and control subjects. Although, it seems 
o be a difference in M6a levels between untreated depressed patients 
r treated with B, there is no statistical significance. In addition, M6a 
evels in depressed patients treated with benzodiazepines were signifi- 
antly higher than in control subjects ( Fig. 3 G, non-parametric ANOVA 
 = 0.0002. Dunn´s multiple comparison test ∗ C vs D + B; ∗ D vs D + SSRI;
 ∗ ∗ D + SSRI vs D + B). These results suggest that M6a levels would be sus-
eptible to change upon pharmacological treatment. 
. Discussion 
In this work, by proteomic analysis of salivary extracellular vesicles, 
e have identified ten protein candidates associated with neuropsychi- 
tric diseases that could serve as biomarkers for such diseases. In ad- 
ition, we have demonstrated that one of those candidates, the protein 
6a, can be quantified in whole saliva. Using patient saliva samples, 
e have shown that M6a levels positively correlated with stress percep- 
ion in depressed patients. Moreover, differences in M6a levels among 
ntidepressant-treated patients suggest a potential M6a use to evaluate 
ntidepressant treatment efficacy. These auspicious findings highlight 
he usefulness of analyzing EVs for new candidate biomarkers discovery 
or mental disorders. 
EVs are secreted by virtually all cells in the organism and are a het- 
rogeneous population of vesicles that transport and deliver proteins 
nd nucleic acids to recipient cells. EVs with different content are re- 
eased into the circulation by cells from healthy and sick subjects. The 
olecules carried by EVs released by pathological cells can be measured 
s disease biomarkers ( Barile and Vassalli, 2017 ). EVs can also cross the 
lood-brain-barrier, thus are an attractive source of biomarkers for brain 
elated disorders ( Alvarez-Erviti et al., 2011 ). Such biomarkers would 
elp clinicians complementing patient evaluation with biochemical pa- 
ameters. It is well known that although clinicians follow Diagnostic and 
tatistical Manual of Mental Disorders (DSM) guidelines and use scales, 
ultiple factors such as patient genetic predisposition, individual fea- 
ures, self-medication and even a trend to conceal symptoms hamper 
iagnosis. This is why easily accessible biomarkers are needed. 
EVs can be isolated from different body fluids, including saliva. 
aliva sampling is not invasive and its collection is easiest and pain- 
ess (e.g. in comparison to blood). The salivary glands are integrated 
nto the neuroendocrine system and contain a wide array of biomarkers 
elated to the pathophysiology of several diseases ( Jasim et al., 2018 ). 
n this work, we focused on those molecules found in salivary EVs re- 
ated to neuronal connectivity, whose alteration is a hallmark of mental 
isorders. 
We found ten brain-enriched proteins. Among them we found 
TR2A, one of the receptors for serotonin, microtubule associated pro- 
ein Tau (MAPT), SLC15A22 a mitochondrial glutamate carrier, several 
roteins involved in myelination (OLIG2, PMP2 and CNP), proteins re- 
ated to pathways involving Ca 2 + signaling (ATP2B2, CAMK2A) and 
he myeloid/lymphoid or mixed-lineage leukemia; translocated to 11 
MLLT11). In addition to their specific role (Supplementary Fig 3), can- 
idates are associated with psychotic and depressive disorders. This sug- 
ests that molecules underlying the pathogenesis of stress-related disor- 
ers could be evaluated in saliva from patients. 
Since M6a participates in neuronal connectivity, has been related to 
epression and has been widely studied by our group, we focused on this 
olecule. First, we confirmed that likewise to serum M6a, salivary M6a 
s also coupled to EVs. Then, we showed that M6a could be measured in 
hole saliva, without the need of EV purification. In a pilot study, we 
ssessed M6a levels in patients diagnosed with depression or anxiety and 
lso in control subjects. Although we did not find statistical differences, 
ome relation between M6a and depression was suggested. 7 Clinical diagnosis of mood disorders is often supported by tests such 
s PSS and HADS-D. Here, we have found that M6a levels positively 
orrelated with the perceived stress scale exclusively in depressed pa- 
ients. This reinforces the idea of M6a as a stress-responsive protein 
hose levels changes when the individual experiences stress. Studies 
ave shown that exposure to stressors increases susceptibility to psy- 
hological disorders ( Alkadhi, 2013 ; Meyer et al., 2013 ). Moreover, re- 
eated or recurrent stress is known to quicken or worsen the mood dis- 
rders ( Khan, 2016 ; McEwen, 2009 ). HPA axis deregulation, a common 
eature of chronic stress, has been found in patients with severe depres- 
ive and psychotic symptoms ( Khan, 2016 ). In the case of depressed 
ndividuals, it has been reported that their depressive state can alter 
esponses to stressors, amplifying the stress perception ( Kumar et al., 
015 ). Thus, M6a levels could represent a measure of such exacerbated 
erception. 
We found a positive correlation between M6a levels and the HADS-D 
cores. HADS D is the most commonly used test for depression screen- 
ng. Notably, the correlation was only observed in the group of patients 
ith higher scores for HADS-D. This suggests that M6a levels could com- 
lement the clinical classification as caseness of depression. 
Evidences suggest that impairing serotonin function can cause clini- 
al depression and can also compromise mechanisms involved in main- 
aining recovery from depression ( Cowen and Browning, 2015 ). We 
ave shown that, in SSRI-treated depressed patients, salivary M6a lev- 
ls were lower than in untreated patients. SSRI increase synaptic plas- 
icity and restore homeostasis attenuating depression symptoms. In- 
erestingly, administration of tricyclic antidepressants (which inhibit 
he reuptake of the biogenic amines, mostly norepinephrine and sero- 
onin) to chronically stressed animals reverts stress and M6a mRNA 
ownregulation ( Alfonso et al., 2004 ). Now, our results suggest that, 
n SSRI-treated depressed patients, M6a might accompany the molec- 
lar changes induced by SSRI. On the other hand, the high salivary 
6a levels in patients treated with benzodiazepines highlight the dif- 
erences in the mechanisms of action for SSRIs and benzodiazepines. 
enzodiazepines act through 𝛾-amino butyric acid (GABA) receptors A, 
acilitating the inhibitory action of GABA. Since reduced GABA levels 
n plasma and cerebrospinal fluid of depressed patients were reported 
 Luscher and Malenka, 2012 ), GABAergic deficits may also contribute to 
epressive disorders. It has been shown that M6a promotes differentia- 
ion of GABAergic neurons ( Michibata et al., 2008 ). It remains unknown 
f M6a may also participate in the benzodiazepine pathway. 
Salivary M6a levels are different between depressed patients and 
epressed patients under SSRI or benzodiazepine treatment. There- 
ore, with further studies, M6a levels might be used in clinical tri- 
ls of patients under SSRI or benzodiazepines treatment. It has been 
eported that biomarkers could complement clinical assessment by 
ighlighting changes in the levels of biomarkers that occur in par- 
llel or ahead of changes in clinical symptoms, allowing physicians 
o make adjustments in therapy quickly ( Carboni et al., 2019 ). For 
xample, it has been shown that saliva levels of norepinephrine 
etabolite3 ‑methoxy-4-hydroxyphenylglycol (sMHPG) are higher in in- 
ividuals with good response to SSRI compared to non-responders, sug- 
esting that sMHPG could be useful to stratify patients for antidepressant 
reatment ( Egami et al., 2013 ). Although the results shown here for M6a 
ave the constraint that patients with different treatment duration were 
ncluded (which adds heterogeneity to the sample), they suggest that 
6a could help in the discrimination between treatments administered. 
This pilot study of M6a as a biomarker in patients diagnosed with 
ental disorders has as its main limitation that it is a retrospective study 
one in a small sample of patients. Thus, evaluation of M6a levels in a 
arger group as well as a longitudinal study is needed. Although in need 
f replication, the present results show that salivary EVs carry brain- 
nriched proteins that could be putative biomarkers of stress-related 
ental disorders. Of the identified proteins, we focused on M6a and 
howed that it could contribute to stress perception in depressed pa- 
ients. In addition, we showed that salivary M6a levels are modulated 


































































n opposite directions by SSRI and benzodiazepines, a result compatible 
o their different actions on neural plasticity. A possible role for salivary 
6a in distinguishing between treatments is also suggested. We hope 
hat this work raises interest in the field of EVs as sources for mood 
isorder biomarker. We believe it would open a new window for the 
iagnosis of neuropsychiatric diseases. 
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